Clinical trials: Zidovudine
HIV Infections
Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given subcutaneously in conjunction with antiviral treatment and to explore the effects of treatment on surrogate markers of efficacy and incidence of…
- Trial name
- NCT00001997
- Testing
- Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
- Where
- United States
- Sponsor
- Chiron Corporation
HIV Infections
A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.
- Trial name
- NCT00002269
- Testing
- Ampligen, Zidovudine
- Where
- 5 sites in United States
- Sponsor
- HEM Research
HIV Infections
A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To evaluate the efficacy of Saquinavir-SGC combination with Zidovudine and Lamivudine in the treatment of HIV-1 infected patients with no previous anti-retroviral drug therapy.
- Trial name
- NCT00002367
- Testing
- Saquinavir, Lamivudine, Zidovudine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Healthy
Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers
The objective of this study was to characterize the effect of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg) administered twice daily on the pharmacokinetics (PK) of zidovudine…
- Trial name
- NCT02249416
- Testing
- Tipranavir (TPV) low, Ritonavir (RTV) low, Tipranavir (TPV) high
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.
- Trial name
- NCT00004998
- Testing
- Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
- Where
- 10 sites in United States, Dominican Republic
- Volunteers
- 30 people
- Sponsor
- Agouron Pharmaceuticals
Acquired Immunodeficiency Syndrome, Anemia
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo in AIDS patients for the treatment of anemia that is a result of the disease or a result of zidovudine (AZT) treatment for AIDS.
- Trial name
- NCT00270270
- Testing
- epoetin alfa
- Volunteers
- 63 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV…
- Trial name
- PEPDar (NCT01516970)
- Testing
- Darunavir/Ritonavir (DRV/r), Lopinavir in fixed combination with Ritonavir, Zidovudine
- Where
- 17 sites in Germany
- Volunteers
- 312 people
- Sponsor
- Janssen-Cilag G.m.b.H
HIV Infections
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.
- Trial name
- NCT00002371
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours or a higher dose every 12 hours.
- Trial name
- NCT00002020
- Testing
- Zidovudine
- Where
- 12 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus I, HIV Infection
GW873140 In Combination With Combivir In HIV Infected Subjects
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.
- Trial name
- NCT00104429
- Testing
- GW873140, Combivir
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 125 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
To offer an investigational agent (saquinavir) to people with HIV/AIDS who are in need of additional treatment options and are not eligible to enroll in ongoing clinical trials.
- Trial name
- NCT00002382
- Testing
- Saquinavir
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Hoffmann-La Roche
Healthy
Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions
The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and GlaxoSmithKline (Retrovir ®) 300 mg Zidovudine tablets, under fed conditions
- Trial name
- NCT00779376
- Testing
- Zidovudine 300mg tablets
- Where
- Canada
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Lymphoma, Non-Hodgkin, HIV Infections
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic…
- Trial name
- NCT00002284
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
To evaluate the safety and efficacy of interferon beta (Betaseron) in AIDS and advanced AIDS related complex (ARC) patients receiving a reduced-dose zidovudine (AZT) regimen.
- Trial name
- NCT00002238
- Testing
- Interferon beta-1b, Zidovudine
- Where
- 25 sites in United States
- Sponsor
- Bayer
Mycobacterium Avium-intracellulare Infection, HIV Infections
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy.
- Trial name
- NCT00000971
- Testing
- Clarithromycin, Zidovudine, Didanosine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Abbott
HIV Infections
A Study of Isoprinosine in Patients With Severe AIDS
To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): Comparison of total helper and suppressor T-cell numbers among the groups.
- Trial name
- NCT00002295
- Testing
- Inosine pranobex
- Where
- United States
- Sponsor
- Newport Pharmaceuticals International
HIV Infections
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on…
- Trial name
- NCT00000628
- Testing
- L-697,661, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Lipodystrophy
Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue
A previous study substituting zidovudine or stavudine to abacavir in patients with severe or moderate lipoatrophy has shown an increase in limb fat by DEXA.
- Trial name
- RAVE (NCT00647946)
- Testing
- tenofovir DF, abacavir 300mg twice daily
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
HIV Infections
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
To assess the dose-related antiviral effects of SC-48334 and zidovudine (AZT) administered in combination or individually in HIV-1 positive patients with 200 - 500 CD4+ cells/mm3.
- Trial name
- NCT00002079
- Testing
- Butyldeoxynojirimycin, Zidovudine
- Where
- 9 sites in United States
- Sponsor
- G D Searle